Author biography; 1 Introduction; References; 2 Therapy options for advanced NSCLC; First-line chemotherapy and anti-angiogenic agents; First-line EGFR tyrosine kinase inhibitors; ALK inhibitors; References; 3 Resistance to EGFR TKIs; Primary resistance to EGFR-TKIs; Acquired resistance to EGFR-TKIs; References; 4 Overcoming EGFR-TKI resistance; Overcoming resistance with EGFR-targeted agents; Overcoming EGFR-TKI resistance by targeting alternate pathways; References; 5 Resistance to crizotinib and therapeutic options; Target-dependent mechanisms; Non-target-dependent mechanisms
Crizotinib beyond progressionSecond-generation ALK inhibitors; Other agents; References; 6 Resistance to anti-angiogenic drugs and therapeutic options; References; 7 Conclusion
Summary
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide
Bibliography
Includes bibliographical references
Notes
Online resource; title from PDF title page (EBSCO, viewed October 22, 2015)
